» Articles » PMID: 35867240

Nanomedicine and Regenerative Medicine Approaches in Osteoarthritis Therapy

Overview
Publisher Springer
Specialty Geriatrics
Date 2022 Jul 22
PMID 35867240
Authors
Affiliations
Soon will be listed here.
Abstract

Osteoarthritis (OA), the most common chronic joint disease, is a degenerative disease that affects 7% of the worldwide population, more than 500 million people all over the world. OA is the main factor of disability in elderly people which decreases the quality of life of patients. It is characterized by joint pain, low bone density, and deterioration of the joint structure. Despite ongoing novel advances in drug discovery and drug delivery, OA therapy is still a big challenge since there is no available effective treatment and the existing therapies mainly focus on pain and symptomatic management rather than improving and/or suppressing its progression. This review aims to summarize the currently available and novel emerging therapies for OA including regenerative medicine and nanotechnology-based materials and formulations at the clinical and experimental levels. Applications of regenerative medicine and novel technologies such as nanotechnology in OA treatments have opened a new window to support OA patients by offering treatments that could halt or delay OA progression satisfactorily or provide an effective cure in near future. Nanomedicine and regenerative medicine suggest novel alternatives in the regeneration of cartilage, repair of bone damage, and control of chronic pain in OA therapy.

Citing Articles

Biocompatibility and photoinactivation evaluation of zinc hydroxide chloride nanosheets against Streptococcus mutans.

Afrasiabi S, Saghatchi F, Dehpour A, Goudarzi R, Karimi M, Partoazar A BMC Microbiol. 2025; 25(1):116.

PMID: 40038584 PMC: 11877797. DOI: 10.1186/s12866-025-03822-x.


MiR-146b-5p enriched bioinspired exosomes derived from fucoidan-directed induction mesenchymal stem cells protect chondrocytes in osteoarthritis by targeting TRAF6.

Lou C, Jiang H, Lin Z, Xia T, Wang W, Lin C J Nanobiotechnology. 2023; 21(1):486.

PMID: 38105181 PMC: 10726686. DOI: 10.1186/s12951-023-02264-9.


Could Hyaluronic Acid Be Considered as a Senomorphic Agent in Knee Osteoarthritis? A Systematic Review.

Bernetti A, Agostini F, Paoloni M, Raele M, Fari G, Megna M Biomedicines. 2023; 11(10).

PMID: 37893231 PMC: 10604344. DOI: 10.3390/biomedicines11102858.


Effects of Terpenes on the Osteoarthritis Cytokine Profile by Modulation of IL-6: Double Face versus Dark Knight?.

Fari G, Megna M, Scacco S, Ranieri M, Raele M, Noya E Biology (Basel). 2023; 12(8).

PMID: 37626947 PMC: 10452224. DOI: 10.3390/biology12081061.


Hemolytic Activity of Nanoparticles as a Marker of Their Hemocompatibility.

Yedgar S, Barshtein G, Gural A Micromachines (Basel). 2022; 13(12).

PMID: 36557391 PMC: 9783501. DOI: 10.3390/mi13122091.

References
1.
Glyn-Jones S, Palmer A, Agricola R, Price A, Vincent T, Weinans H . Osteoarthritis. Lancet. 2015; 386(9991):376-87. DOI: 10.1016/S0140-6736(14)60802-3. View

2.
Hunter D, Bierma-Zeinstra S . Osteoarthritis. Lancet. 2019; 393(10182):1745-1759. DOI: 10.1016/S0140-6736(19)30417-9. View

3.
Buttgereit F, Burmester G, Bijlsma J . Non-surgical management of knee osteoarthritis: where are we now and where do we need to go?. RMD Open. 2015; 1(1):e000027. PMC: 4613167. DOI: 10.1136/rmdopen-2014-000027. View

4.
Luo J, Zhang Y, Zhu S, Tong Y, Ji L, Zhang W . The application prospect of metal/metal oxide nanoparticles in the treatment of osteoarthritis. Naunyn Schmiedebergs Arch Pharmacol. 2021; 394(10):1991-2002. PMC: 8486704. DOI: 10.1007/s00210-021-02131-0. View

5.
Mobasheri A, Batt M . An update on the pathophysiology of osteoarthritis. Ann Phys Rehabil Med. 2016; 59(5-6):333-339. DOI: 10.1016/j.rehab.2016.07.004. View